Nanosyn to Provide Small Molecule Libraries for Euroscreen's GPCR Research
According to Jim Ostrem, VP of Nanosyn, the collaboration will combine Nanosyn's lead discovery libraries with Euroscreen's access to novel and proprietary receptors in a very important class of biological targets. "This gives us the opportunity to maximize the potential of our in-house collection and apply our proprietary synthesis platform to demonstrate the speed with which initial leads discovered in screening can be turned into high affinity ligands," Ostrem said.
"In addition to various sources of biological compounds, we now have access to a collection of approximately 100,000 small molecule ligands that we can use to begin the process of identifying novel agonists and antagonists in high throughput screening assays at Euroscreen," said Pierre Nokin, CEO of Euroscreen. "Our goal is to provide pharmaceutical and biotechnology companies with both relevant receptors and small molecule ligands which can be used to validate the role these receptors play in disease processes."
Nanosyn was established in 1998 by a group of scientists with expertise in combinatorial organic synthesis, analysis of combinatorial libraries, and high throughput screening. The company has developed a proprietary platform for combinatorial synthesis, Accelerated Nanoscale Synthesis Technology (ANST), which streamlines the interface between the synthesis of diverse collections of organic compounds with drug-like characteristics and high throughput screening assays.
Euroscreen was founded in 1994 as a spin-off of the Brussels University School of Medicine. The founding scientists of the company, Gilbert Vassart and Marc Parmentier, are well known for their pioneering work in PCR based homology cloning. The company currently has more than 100 cloned GPCRs in stable, transfected cell lines.
For more information: Jim Ostrem, Vice President, Nanoscale Combinatorial Synthesis Inc., 9062 S. Rita Rd., Tucson, AZ 85747. Tel: 520-799-7621. Fax: 520-799-7616.